With a market cap of $84.3 billion, Marsh & McLennan Companies, Inc. (MRSH) is a global professional services firm that provides advisory and insurance solutions across risk, strategy, and people. The company operates through Risk and Insurance Services and Consulting segments, serving a wide range of clients worldwide.
Marsh & McLennan is set to announce its fiscal Q1 2026 results before the market opens on Thursday, Apr. 16. Ahead of this event, analysts forecast MRSH to report an adjusted EPS of $3.22, a rise of 5.2% from $3.06 in the year-ago quarter. It has exceeded Wall Street's earnings estimates in the last four quarters.
For fiscal 2026, analysts expect the insurance broker to post an adjusted EPS of $10.34, up 6.1% from $9.75 in fiscal 2025. In addition, adjusted EPS is anticipated to grow 8.9% year-over-year to $11.26 in fiscal 2027.
Shares of Marsh & McLennan have declined nearly 27% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 14.5% increase and the State Street Financial Select Sector SPDR ETF's (XLF) 2.2% decrease over the same period.
Shares of Marsh & McLennan rose 5.5% on Jan. 29 after the company reported strong Q4 2025 results, with net income increasing to $821 million ($1.68 per share) from $788 million ($1.59 per share) a year earlier. Total revenue climbed 9% to $6.6 billion, driven by a 9% rise in its risk and insurance services segment to $4 billion and an 8% gain in its consulting business. The results were supported by continued demand for insurance policies despite higher premiums, reflecting resilience in a tough macroeconomic environment.
Positive sentiment was further supported by steady segment performance, strategic progress (including the McGriff integration and new brand launch), and management’s optimistic outlook for sustained momentum in 2026.
Analysts' consensus view on MRSH stock is cautiously optimistic, with a "Moderate Buy" rating overall. Among 25 analysts covering the stock, seven recommend "Strong Buy," 17 "Holds," and one suggests "Moderate Sell." The average analyst price target for Marsh & McLennan is $208.28, suggesting a potential upside of 17.9% from current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
- Netflix Could Be Setting Up for a Big Show, But I’m Not Convinced the Move Will Be Up. Here’s Why.
- Analysts Expect Higher TPU Shipments. Why That Makes Broadcom Stock a Buy Now.
- Costco Is Launching Standalone Gas Stations. Why the Heck Does Wall Street Care?
- Is Mark Zuckerberg Using AI to Replace Himself as CEO? New Agent Paints Grim Picture for Workers as Job Cuts Loom.
